Page 12 - Systemic Sclerosis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

REGULATED INFORMATION Mont-Saint-Guibert, Belgium, January 27, 2023, 7am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company...

Guidelines could tailor cardiovascular risk scores by using a multiplier of 2.5 for systemic sclerosis, 2.0 for lupus, and 1.5 for any other rheumatic disease.

More than 110 pulmonologists, rheumatologists and radiologists and three international speakers focused on the latest scientific guidelines to improve the clinical outcomes for patients living with rare respiratory conditions at a Dubai event.

/PRNewswire/ -- Systemic Sclerosis (Scleroderma) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top...

Systemic sclerosis, also known as scleroderma, is a rare and complex autoimmune connective-tissue disease. Once considered an untreatable and unpredictable condition, research advancements have improved our understanding of its disease pathogenesis and clinical phenotypes and expanded our treatment armamentarium. Early and accurate diagnosis is essential, while ongoing efforts to risk stratify patients have a central role in predicting both organ involvement and disease progression. A holistic approach is required when choosing the optimal therapeutic strategy, balancing the side-effect profil...